Shanshan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shanshan Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Yun Luan
Institute of Medical Sciences, The Second Hospital of Shandong University, No. 247, Beiyuan Dajie, Jinan, 250000, PR China
2 shared publications - Caixia Liu
Research Center of China Medical University Birth Cohort, Shengjing Hospital of China Medical University, Shenyang, China.
1 shared publication - Chao Sun
Central Research Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University, No. 247, Beiyuan Dajie, Jinan, 250033, China
1 shared publication - Chao Yu
School of Geographic Sciences, Xinyang Normal University, Xinyang 464000, China
1 shared publication - Chaoyue Xu
Department of Nursing, University of South China , 28 Changshengxi Road, Hengyang, Hunan 421001
1 shared publication Guofeng Wan
Nanchang Qinghu Sub-branch, Bank of China, Nanchang, 330096, China
1 shared publication
Latest Publications
- 9 May 2023
- Published by Elsevier in Resources Policy
- Vol. 83, 103671
Combining the role of the banking sector and natural resource utilization on green economic development: Evidence from China
- 9 May 2023
- Published by Elsevier in Resources Policy
- Vol. 83, 103671
Combining the role of the banking sector and natural resource utilization on green economic development: Evidence from China
- 2 September 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (12) , 1654-1662
Mesenchymal Stromal Cell-derived Exosomes Attenuate Experimental Pulmonary Arterial Hypertension
Background: Pulmonary arterial hypertension (PH) is a chronic disease that ultimately progresses to right ventricular failure and death, until now there is still lack of effective treatment applied. The purpose of the present study was to observe the protective effect of mesenchymal stromal cell derived exosomes (MSC-EXO) against experimental pulmonary arterial hypertension (PH) and right ventricular failure. Methods: All the experimental rats received an intraperitoneal injection of 50 mg/kg monocrotaline to induce PH model. Three weeks after the model was successfully established, the cell Culture Media (CM) or MSC-EXO derived from human umbilical cord was administered daily via the tail vein. All animals were randomly divided into 4 groups: Control (saline-treated), MCT-PH, MCT-CM and MCT-EXO groups. Post-operation, hemodynamic data and index of right ventricular hypertrophy (RVHI) were recorded to evaluate the inhibition of MSC-EXO on MCT-induced PH. Histology, immunohistochemistry and western blot were used to analyze the effect of MSC-EXO against vascular remodeling and further reveal the mechanism. Results: In the present study, our results showed that MSC-EXO administration could significantly reduce the right ventricular systolic pressure (RVSP) and RVHI, suppress the pulmonary vascular remodeling and the endothelialmesenchymal transition (EndMT) process. Conclusion: Our results provided the firm information for a new method in treatment of PH, the mechanism may be may be related with the inhibition of vascular remodeling and EndMT.
- 2 September 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (12) , 1654-1662
Mesenchymal Stromal Cell-derived Exosomes Attenuate Experimental Pulmonary Arterial Hypertension
Background: Pulmonary arterial hypertension (PH) is a chronic disease that ultimately progresses to right ventricular failure and death, until now there is still lack of effective treatment applied. The purpose of the present study was to observe the protective effect of mesenchymal stromal cell derived exosomes (MSC-EXO) against experimental pulmonary arterial hypertension (PH) and right ventricular failure. Methods: All the experimental rats received an intraperitoneal injection of 50 mg/kg monocrotaline to induce PH model. Three weeks after the model was successfully established, the cell Culture Media (CM) or MSC-EXO derived from human umbilical cord was administered daily via the tail vein. All animals were randomly divided into 4 groups: Control (saline-treated), MCT-PH, MCT-CM and MCT-EXO groups. Post-operation, hemodynamic data and index of right ventricular hypertrophy (RVHI) were recorded to evaluate the inhibition of MSC-EXO on MCT-induced PH. Histology, immunohistochemistry and western blot were used to analyze the effect of MSC-EXO against vascular remodeling and further reveal the mechanism. Results: In the present study, our results showed that MSC-EXO administration could significantly reduce the right ventricular systolic pressure (RVSP) and RVHI, suppress the pulmonary vascular remodeling and the endothelialmesenchymal transition (EndMT) process. Conclusion: Our results provided the firm information for a new method in treatment of PH, the mechanism may be may be related with the inhibition of vascular remodeling and EndMT.
- 28 November 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (13) , 1386-1393
The Protective of Baicalin on Myocardial Ischemia-Reperfusion Injury
Background: The aim of this study was to explore the inhibitory effect of baicalin on myocardial apoptosis induced by Ischemia-Reperfusion (I/R).Methods: Sprague Dawley rats' heart and myocardial cells I/R model were established in vivo and vitro, then 100 mg/kg and 10 μmol/l baicalin were administrated, respectively. The experiment was randomly divided into 4 groups (n=10): Control; I/R; IR+DMEM; and I/R+baicalin groups. Postoperation, the Left Ventricular (LV) End-Diastolic Pressure (LVEDP), the maximum velocity of LV contraction (dP/dtmax) and the maximum velocity of LV diastole (dP/dtmin) were recorded by the transthoracic echocardiography; the myocardial apoptosis percentage was analyzed by Annexin VFITC/ PI and TUNEL staining, and the apoptosis gene and protein were detected by RT-PCR and western blot. Furthermore, the protein expression of the calcium-sensing receptor (CaSR) and ERK1/2 phosphorylation were observed by western blot and Fura-2-acetoxymethyl ester. Moreover, primary rats’ cardiomyocytes were cultured and ERK1/2 specific inhibitor PD98059 was added to the culture medium. The cell survival rate, vitality and apoptosis were detected by MTT, lactate dehydrogenase (LDH) and TUNEL staining assay Kit, respectively.Results: Our present study showed that baicalin significantly improved LV hemodynamic parameters and myocardial apoptosis in myocardial I/R injury rats. Furthermore, we found that baicalin could down-regulate the protein expression of CaSR, but up-regulate the protein expression of ERK1/2. Furthermore, when the cells were pretreated with ERK1/2 inhibitor PD98059, the cells survival rate significantly decreased, but LDH activity and apoptosis significantly increased. The results indicated that the effect of baicalin on myocardial I/R injury could be inhibited by ERK1/2 inhibitor.Conclusion: In conclusion, our data suggests that baicalin attenuates I/R-induced myocardial injury maybe through the suppression of the CaSR/ERK1/2 signaling pathway.
- 28 November 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (13) , 1386-1393
The Protective of Baicalin on Myocardial Ischemia-Reperfusion Injury
Background: The aim of this study was to explore the inhibitory effect of baicalin on myocardial apoptosis induced by Ischemia-Reperfusion (I/R).Methods: Sprague Dawley rats' heart and myocardial cells I/R model were established in vivo and vitro, then 100 mg/kg and 10 μmol/l baicalin were administrated, respectively. The experiment was randomly divided into 4 groups (n=10): Control; I/R; IR+DMEM; and I/R+baicalin groups. Postoperation, the Left Ventricular (LV) End-Diastolic Pressure (LVEDP), the maximum velocity of LV contraction (dP/dtmax) and the maximum velocity of LV diastole (dP/dtmin) were recorded by the transthoracic echocardiography; the myocardial apoptosis percentage was analyzed by Annexin VFITC/ PI and TUNEL staining, and the apoptosis gene and protein were detected by RT-PCR and western blot. Furthermore, the protein expression of the calcium-sensing receptor (CaSR) and ERK1/2 phosphorylation were observed by western blot and Fura-2-acetoxymethyl ester. Moreover, primary rats’ cardiomyocytes were cultured and ERK1/2 specific inhibitor PD98059 was added to the culture medium. The cell survival rate, vitality and apoptosis were detected by MTT, lactate dehydrogenase (LDH) and TUNEL staining assay Kit, respectively.Results: Our present study showed that baicalin significantly improved LV hemodynamic parameters and myocardial apoptosis in myocardial I/R injury rats. Furthermore, we found that baicalin could down-regulate the protein expression of CaSR, but up-regulate the protein expression of ERK1/2. Furthermore, when the cells were pretreated with ERK1/2 inhibitor PD98059, the cells survival rate significantly decreased, but LDH activity and apoptosis significantly increased. The results indicated that the effect of baicalin on myocardial I/R injury could be inhibited by ERK1/2 inhibitor.Conclusion: In conclusion, our data suggests that baicalin attenuates I/R-induced myocardial injury maybe through the suppression of the CaSR/ERK1/2 signaling pathway.
- 1 January 2016
- Published by Wolters Kluwer Health
- Vol. 51 (1) , 18-22
[Prenatal diagnosis and intervention to fetal hydrothorax: five cases analysis].
To research the important of prenatal diagnosis and effect of intervention to fetal hydrothorax. The cases of fetal hydrothorax (n=5) were obtained from the Shengjing Hospital, China Medical University between December 2014 and May 2015. All pregnancies were uncomplicated, excluded congenital organic and chromosomal abnormalities during prenatal diagnosis and with a 37 average gestational weeks. The case 1, 2, 4 were unilateral hydrothorax and the case 3, 5 were bilateral. We performed an antenatal thracocentesis to case 1, 2, 3. In case1, the hydrothorax increased rapidly after 5 days, and the patient underwent a cesarean section and ex utero intrapartum treatment (EXIT); in case 2, the fetal heart rate was decreased to 40-50 bpm suddenly during thracocentesis, and we performed an emergent cesarean section and EXIT for the patient; in case 3, the patient underwent thracocentesis and a meanwhile cesarean section and EXIT procedure. We performed a conservative management to case 4, 5, the hydrothorax resolved spontaneously during the pregnancy and after birth, both patients underwent cesarean section. All fetuses were survived, the neonates of case 1, 2 and 3 underwent assited mechanical ventilation, thoracic close drainage, then discharged after hydrothorax resolved and feeding tolerance; in case 4, there was no respiratory distress and hospital treatment; in case 5, the neonate underwent assited mechanical ventilation and conservative management, the hydrothorax has resolved gradually. The prenatal diagnosis and antenatal intervention (thracocentesis) may play an important role in fetal hydrothorax treatment. In clinical, we should choose different plan according to the gestation weeks and classification of hydrothorax of the patient.
- 1 January 2016
- Published by Wolters Kluwer Health
- Vol. 51 (1) , 18-22
[Prenatal diagnosis and intervention to fetal hydrothorax: five cases analysis].
To research the important of prenatal diagnosis and effect of intervention to fetal hydrothorax. The cases of fetal hydrothorax (n=5) were obtained from the Shengjing Hospital, China Medical University between December 2014 and May 2015. All pregnancies were uncomplicated, excluded congenital organic and chromosomal abnormalities during prenatal diagnosis and with a 37 average gestational weeks. The case 1, 2, 4 were unilateral hydrothorax and the case 3, 5 were bilateral. We performed an antenatal thracocentesis to case 1, 2, 3. In case1, the hydrothorax increased rapidly after 5 days, and the patient underwent a cesarean section and ex utero intrapartum treatment (EXIT); in case 2, the fetal heart rate was decreased to 40-50 bpm suddenly during thracocentesis, and we performed an emergent cesarean section and EXIT for the patient; in case 3, the patient underwent thracocentesis and a meanwhile cesarean section and EXIT procedure. We performed a conservative management to case 4, 5, the hydrothorax resolved spontaneously during the pregnancy and after birth, both patients underwent cesarean section. All fetuses were survived, the neonates of case 1, 2 and 3 underwent assited mechanical ventilation, thoracic close drainage, then discharged after hydrothorax resolved and feeding tolerance; in case 4, there was no respiratory distress and hospital treatment; in case 5, the neonate underwent assited mechanical ventilation and conservative management, the hydrothorax has resolved gradually. The prenatal diagnosis and antenatal intervention (thracocentesis) may play an important role in fetal hydrothorax treatment. In clinical, we should choose different plan according to the gestation weeks and classification of hydrothorax of the patient.